Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2026
US WorldMeds acquires Orbus Therapeutics
US WorldMeds acquired Orbus Therapeutics, adding Orbus' late-stage eflornithine program for recurrent Grade 3 astrocytoma to its rare-disease portfolio. Orbus became a wholly owned subsidiary of US WorldMeds.
2020
US WorldMeds announces partnership to provide LUCEMYRA to patients in need
US WorldMeds announced a partnership with FEMA and Healthcare Ready and, with FEMA and its partnership with Healthcare Ready, is donating approximately $500,000 worth of LUCEMYRA to VIP Community Services in the Bronx for eligible patients facing unplanned opioid withdrawal to access at no charge.